Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance
- 25 October 2018 - 1 mins read
Paris (France), 25 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2018.
Financial highlights
- Q3 2018 Group sales growth of 20.2%1 driven by Specialty Care sales growth of 24.2%1 reflecting strong momentum for Somatuline® and Dysport®, continued sequential sales growth for Cabometyx® and Onivyde®, and growth of Consumer Healthcare sales of 5.0%2
- YTD Group sales growth of 21.1%1 fueled by strong Specialty Care sales growth of 25.8%1 and Consumer Healthcare sales growth of 2.9%2
- Full Year 2018 guidance confirmed with Group sales growth of greater than 19.0%1 and core operating margin of around 29.0% of sales
Pipeline highlights
- Positive CHMP (Committee for Medicinal Products for Human Use) opinion for Cabometyx® for the treatment of second-line patients with hepatocellular carcinoma (HCC)
- First European approval for the new Somatuline® delivery system
Attachment
Related Documents
14 October 2024
1 mins read
Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022
1 mins read
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021
1 mins read
Ipsen announces the launch of an Employee Shareholding Plan